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Abstract
USA300 is an epidemic community-acquired methicillin-resistant Staphylococcus aureus (C-MRSA) clone in the USA, whereas the Euro-
pean C-MRSA clone ST80-IV has mainly a sporadic diffusion in Europe. The prevalence of European clone ST80-IV in Algeria is poorly
documented. We prospectively studied S. aureus infections at Mustapha Bacha hospital in Algiers over a 20-month period. S. aureus nasal
colonization was studied during a further 6-month period. The European clone ST80-IV was responsible for more than one-third of
both community infections (35.7%) and hospital infections (35.8%). Panton–Valentine leukocidin (PVL)-positive MRSA isolated from hos-
pital inpatients were resistant to multiple antibiotics, including ﬂuoroquinolones in 44.9% of cases. The PVL-positive MRSA nasal carriage
rate was high among patients and staff in the dermatology unit (8.7% and 18.5%, respectively), but low (2.7%) among patients attending
the outpatient clinic. The European PVL-positive C-MRSA clone ST80-IV is widespread in the Algiers hospital and community settings.
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Introduction
Staphylococcus aureus is the main cause of suppurative infec-
tions due to secreted toxins. Community-acquired methicil-
lin-resistant S. aureus strains (C-MRSA) are spreading
worldwide, in the form of a limited number of clones, includ-
ing USA300 in the USA, ST80-IV in Europe, and the South-
west Paciﬁc clone in Asia and Oceania [1,2]. New C-MRSA
clones are continually emerging [1], and most of them pos-
sess the Panton–Valentine leukocidin (PVL) genes. These
PVL-positive C-MRSA clones are commonly responsible for
skin and soft-tissue infections, but can also cause life-threat-
ening infections such as necrotizing pneumonia [3], fasciitis
[4], and bone and joint infections [5,6].
The prevalence of MRSA in the community varies consid-
erably from one country to another. In the USA, MRSA have
been isolated from up to 59% of patients with community-
acquired infections [7]. The prevalence is generally low in
Europe but reaches 45% in Greece [8]. In the USA and
Greece, PVL-positive MRSA have also become prevalent in
hospitals, accounting for, respectively, 8% and 25% of isolates
[9,10], thus blurring the historical distinction between hospi-
tal- and community-acquired MRSA. Once established in the
hospital environment, C-MRSA frequently becomes resistant
to multiple antibiotics, including ﬂuoroquinolones [11–13].
In Algeria, the European clone ST80-IV has been detected
[14]. Most Algerian PVL-positive MRSA isolates are resistant
to kanamycin, tetracycline and fusidic acid, and resistance to
ﬂuoroquinolones has also been described in hospital isolates
[14]. To assess the prevalence of PVL-positive MRSA in Alge-
ria, we conducted a prospective study at Mustapha Pacha
hospital in the capital, Algiers, from April 2006 to December
2007.
Materials and Methods
Patients and MRSA isolates
From April 2006 to December 2007, a total of 700 S. aureus
isolates (all found during the study period) were recovered
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from 663 patients at Mustapha Bacha University Hospital, a
1800-bed facility located in Algiers. As deﬁned by the Cen-
ters for Disease Control and Prevention (Atlanta, GA,
USA), a case was considered to be community-acquired (by
analysis of paper-based patient records) when MRSA infec-
tion was identiﬁed <48 h after admission in a patient with
no history of hospitalization, surgery, catheterization, pros-
thesis placement or positive MRSA culture in the previous
year. The characteristics recorded in an epidemiological
database were: gender, date of birth, type of sample, diagno-
sis, and ward. Written informed consent to participate in
the study was obtained from the patient or guardians, and
the protocol was approved by the ethics committee of
Mustapha Bacha Hospital. Two hundred and twenty-one
S. aureus isolates were randomly selected for further analy-
sis. S. aureus identiﬁcation was based on colony morphology,
microscopic examination, and the coagulase rabbit plasma
and Staphyslide agglutination tests (bioMe´rieux, Marcy
l’Etoile, France).
Nasal carriage screening
From January to June 2008, 105 consenting patients and 27
volunteer staff of the dermatology unit were prospectively
screened for S. aureus nasal carriage. During the same per-
iod, 300 consenting adults attending the outpatient clinic
were also screened. None of these 432 adults was being
treated for S. aureus infection. The nasal samples were
obtained with a sterile cotton swab and processed in the
bacteriology department within 4 h.
Antimicrobial susceptibility testing
Susceptibility to penicillin, oxacillin, cefoxitin, kanamycin,
tobramycin, gentamicin, erythromycin, clindamycin, tetracy-
cline, oﬂoxacin, fosfomycin, trimethoprim/sulfamethoxazole
and rifampicin was determined by the disk diffusion method,
as recommended by the CLSI [15]. Comite´ de l’Antibio-
gramme de la Socie´te´ Franc¸aise de Microbiologie interpreta-
tive criteria were used for pristinamycin and fusidic acid
[16].
DNA extraction and agr allele detection
The isolates were grown on brain-heart infusion agar or in
brain-heart infusion broth at 37C overnight. Genomic DNA
was extracted with a standard procedure [17]. Ampliﬁcation
of gyrA was used to conﬁrm the quality of each DNA extract
and the absence of PCR inhibitors. All PCR products were
analyzed by electrophoresis on ethidium bromide-stained 1%
agarose gels (Sigma, Lyon, France). The accessory gene regu-
lator alleles (agr types 1–4) were detected by PCR as
described previously [17].
MecA gene detection and SCCmec typing
The mecA gene coding for methicillin resistance was
detected by PCR as described previously [18]. The staphylo-
coccal chromosomal cassette mec (SCCmec I-IV) was
detected as described by Oliveira et al. [19], and the
SCCmec type V was detected as described previously [20].
The S. aureus reference strains used as controls were: COL
(SCCmec I), BK2464 (SCCmec II), HU106 (SCCmec III) and
BK2529 (SCCmec IV).
Detection of toxin genes
PCR was used to detect 22 speciﬁc staphylococcal virulence
genes, as described previously [17,21]. The isolates were
screened for sequences speciﬁc for staphylococcal entero-
toxin genes, as well as the toxic-shock syndrome toxin gene
(tst), exfoliative toxin genes, PVL genes, lukE-lukD leukocidin
genes, the class F lukM leukocidin gene, hemolysin genes, and
epidermal cell differentiation inhibitor (edin) genes.
PFGE ﬁngerprinting
SmaI macrorestriction patterns were obtained with a con-
tour-clamped homogeneous electric ﬁeld system (DR-II;
Bio-Rad, Hercules, CA, USA), as described previously [22].
Resolved macrorestriction patterns were compared as rec-
ommended by Tenover et al. [23]. Strains that differed by up
to three fragments were considered to be subtypes of the
same clonal type.
Spa typing
Spa typing was performed as described previously [24,25].
The x region of the spa gene was ampliﬁed by PCR and the
spa type was determined with RIDOM STAPH TYPE software (Ri-
dom GmbH, Wu¨rzburg, Germany).
Multilocus sequence typing
Multilocus sequence typing was performed on representative
strains of each clonal group, as described previously [26].
The allelic proﬁle of each strain was obtained by sequencing
internal fragments of seven housekeeping genes that deﬁned
sequence types [26]. Similar sequence types were grouped
together into clonal complexes.
Statistical analysis
Continuous variables are expressed as medians and inter-
quartile ranges, and categorical variables as frequencies and
percentages. Nonparametric tests were used to compare dis-
tributions (chi-square test or Fisher’s exact test for categori-
cal variables; and Student’s t-test, after log transformation if
necessary). p <0.05 was considered statistically signiﬁcant. All
analyses were performed using EPIINFO software, version 3.4.3
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(Centers of Disease Control and Prevention, Atlanta, GA,
USA).
Results
Clinical characteristics of community and hospital infections
due to both methicillin-susceptible (MSSA) and – resistant
(MRSA) Staphylococcus aureus strains
The 221 S. aureus infections were community-acquired in
38% of cases (n = 84) and hospital-acquired in 62% of cases
(n = 137). The most frequent diagnoses were skin and soft-
tissue infections (75% and 69.4%, respectively, of community
and hospital infections), bone and joint infections (9.5% and
12.4%), bacteraemia (3.5% and 8.7%), pneumonia (6% and
4.4%) and others (6.0% and 5.1%); none of these differences
was statistically signiﬁcant. Most community infections were
diagnosed in the emergency room or during outpatient visits
(53.6%) or in medical wards (36.9%), whereas most hospital
infections were diagnosed in medical (65%) or surgical
(20.4%) wards (data not shown).
Prevalence and characteristics of community and hospital
MRSA infections
MRSA accounted for 40.5% (n = 34) of the 84 community
infections and for 47.4% (n = 65) of the 137 hospital infec-
tions (no signiﬁcant difference, table 1). Patients with C-
MRSA infections were signiﬁcantly younger than patients with
hospital MRSA infections. Skin and soft-tissue infections were
signiﬁcantly more frequent among patients with C-MRSA than
among patients with C-MSSA (p <0.05, table 1). None of the
other studied characteristics were signiﬁcantly different
between the four subgroups of patients. Community isolates
were PVL-positive MRSA in 35.7% of cases (30/84) and PVL-
positive MSSA in 14.3% of cases (12/84) (Table 2). Hospital
isolates were PVL-positive MRSA in 35.8% of cases (49/137)
and PVL-positive MSSA in 5.8% of cases (8/137). Thus, the
proportion of PVL-positive isolates among all S. aureus infec-
tions was 41.6% (57/137) in the hospital and 50.0% (42/84) in
the community (no signiﬁcant difference; Table 2).
MRSA characteristics
All PVL-positive MRSA were agr type 3, and most (n = 79)
were positive for the exfoliative toxin D (etd) and edin genes.
The SCCmec cassette was always type IV. The spa type was
determined for 46 isolates, of which 45 were spa t044 and
one was spa t4143 (related to spa t044). The sequence type
was determined for ten isolates and was always ST80. All
these characteristics were consistent with those of the Euro-
pean clone ST80-IV (Fig. 1).
PVL-negative MRSA were agr type 1 (n = 3, 75%) or agr 3
(n = 1, 25%) in the community, and agr 1 (n = 8, 50%), agr 2
(n = 7, 43.7%) or agr 3 (n = 1, 6.3%) in the hospital. Nine
agr 1 isolates were related to the Hungarian clone [27]: they
possessed an SCCmec type III cassette, the selk and selq
genes, and ST241 (a single-locus variant of clone ST239).
Two agr 1 isolates were ST8, possessed the sea genes and
an SCCmec type V cassette, and were related to the Lyon
clone described by Ferry et al. [27]. Seven agr 2 isolates had
characteristics of the paediatric clone [27], possessing an
TABLE 1. Baseline characteristics in 122 cases of methicillin-resistant Staphylococcus aureus (MRSA) and 89 cases of methicil-
lin-susceptible S. aureus (MSSA) community- and hospital-acquired infections among patients admitted to Mustapha Bacha
Hospital, Algiers, between April 2006 and December 2007
Characteristic
Community infections Hospital infections
MSSA MRSA MSSA MRSA
n % n % n % n %
Staphylococcus aureus isolates 50 59.5 34 40.5 72 52.6 65 47.4
Demographics
Median age (years) 39.9 34.7* 38.6 41.3*
Sex ratio (M/F) 1.94 (33/17) 1.27 (19/15) 1.32 (41/31) 2.09 (44/21)
Diagnosis
Skin/soft-tissue infection 33 66** 30 88** 50 70 45 69
Bone/joint infection 7 14 1 3 8 11 9 14
Bacteraemia 3 6 0 0 7 10 4 6
Pneumonia 3 6 2 6 2 3 5 7
ENT or eye infection 3 6 0 0 3 4 1 2
Meningitis 0 0 1 3 1 1 1 2
Urinary tract infection 1 2 0 0 1 1 0 0
*p <0.05, community-acquired MRSA vs. hospital MRSA.
**p <0.05, MSSA vs. MRSA community infections.
ENT, ear, nose and throat.
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SCCmec type IV cassette and, in most cases, the selm and
selo genes. The two agr 3 MRSA isolates had all the charac-
teristics of the clone ST80-IV apart from the PVL genes.
Hence, except for the two MRSA isolates belonging to clone
ST80-IV, the other 18 PVL-negative MRSA isolates belonged
to well-known epidemic hospital clones.
Antibiotic resistance and characteristics of ﬂuoroquinolone-
resistant PVL-positive MRSA strains
Twenty-two (44.9%) of the 49 PVL-positive H-MRSA isolates
exhibited resistance to ﬂuoroquinolones, whereas no ﬂuor-
oquinolone resistance was noted among the 30 PVL-positive
C-MRSA isolates. The characteristics of 22 ﬂuoroquinolone-
resistant PVL-positive MRSA isolates were compared with
those of 24 ﬂuoroquinolone-susceptible PVL-positive MRSA
isolates to determine whether a speciﬁc clone was spreading
within the hospital. PFGE failed to segregate the two resis-
tance phenotypes into distinct populations, with some pulso-
types being shared by resistant and susceptible isolates
(Fig. 1). This indicated that the resistant strains did not corre-
spond to a speciﬁc PFGE type. Fluoroquinolone-resistant
PVL-positive MRSA strains were more resistant to kanamycin,
tobramycin, gentamicin, erythromycin and fusidic acid
than were ﬂuoroquinolone-susceptible strains (Table 3).
Fluoroquinolone-susceptible strains were more resistant to
tetracycline than were ﬂuoroquinolone-resistant strains.
We also compared the clinical and demographic
characteristics of patients with ﬂuoroquinolone-susceptible
and -resistant PVL-positive MRSA infections. Fluoroquino-
lone-resistant isolates were associated with older age (med-
ian 46.6 and 35.7 years, p <0.05) and with medical wards
(found only in the dermatology unit), but not with a particu-
lar type of infection.
Nasal carriage
S. aureus nasal carriage was detected in 52 (50%) of 104
patients hospitalized in the dermatology ward. Twenty-three
of the 52 isolates (22.1%) were MRSA, of which nine (8.7%)
were PVL-positive; four of these nine patients had secondary
infections due to PVL-positive MRSA. Interestingly, one
patient harboured both PVL-positive and PVL-negative MRSA
strains. S. aureus nasal carriage was associated with a higher
risk of S. aureus infection: 12 infections on 52 colonized
patients vs. no infection on 52 patients without S. aureus
nasal carriage (inﬁnite relative risk). Nine (33.3%) of the 27
dermatology unit staff members were S. aureus carriers; six
isolates were MRSA (22.2%) and ﬁve were PVL-positive
MRSA (18.5%), one of which was also resistant to ﬂuoroqui-
nolones. Seventy-ﬁve (25%) of the 300 outpatients screened
for S. aureus carriage were positive, of whom ten (3.3%) car-
ried MRSA and six (2.7%) carried PVL-positive MRSA. None
of the PVL-positive MRSA isolated from outpatients were
ﬂuoroquinolone-resistant.
Discussion
The present study shows that USA300 is not the unique C-
MRSA clone to exhibit enhanced capacity to cause wide-
spread epidemic diseases and that C-MRSA clone ST80-IV
accounts for more than one-third of infections in an Algiers
hospital and in the surrounding community (35.7% and
35.8%, respectively).
It has been suggested that type I ACME could contribute
to the epidemic character initially unique to USA300.
Because the type I ACME is not found in clone ST80-IV,
other shared characteristics must explain the epidemic pro-
pensity of clones ST80-IV and USA300 [28].
Seven hundred cases of S. aureus infection were included
in this 20-month study. Most cases (69–75%) involved skin
infections. The ﬁrst case of necrotizing pneumonia due to
C-MRSA was observed in Algiers in 2002. In the USA, the
annual number of emergency room visits for skin and
soft-tissue infections nearly tripled between 1993 and 2005,
coinciding with the emergence of C-MRSA. Thus, it appears
that C-MRSA may be causing more disease than displacing
other organisms from preexisting ecological niches [29].
As observed by Liu et al. [30], S. aureus infection tends to
affect males more than females. The median age of our
patients was 38–40 years overall: 46.6 years among those
with ﬂuoroquinolone-resistant PVL-positive MRSA infection,
and 34.7 years among those with C-MRSA infection.
The PVL-positive MRSA isolates had characteristics of
European clone ST80-IV. This clone has previously been
TABLE 2. Panton–Valentine leukocidin (PVL) genes in 221
Staphylococcus aureus isolates recovered from patients
admitted to Mustapha Bacha Hospital, Algiers, between
April 2006 and December 2007
Characteristic
Community
infections
Hospital
infections
p-valuen % n %
All Staphylococcus aureus 84 137
PVL-positive 42 50.0 57 41.6 Ns
PVL-negative 42 50.0 80 58.4
All MSSA 50 72
PVL-positive 12 14.3 8 5.8 0.06
PVL-negative 38 45.2 64 46.7
All MRSA 34 65
PVL-positive 30 35.7 49 35.8 0.13
PVL-negative 4 4.8 16 11.7
MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
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detected in Algeria [31] and Tunisia, and in the Middle East
[32]. Sporadic cases of ST80-IV infection reported in many
European countries often involve travelers from these coun-
tries. For example, clone ST80-IV has been introduced into
Denmark from the Middle East on more than one occasion
[33].
Hospital-acquired PVL-positive MRSA infections in our
study were due to ﬂuoroquinolone-resistant strains in 44.9%
of cases. These isolates did not correspond to a speciﬁc
PFGE type or subtype. Multidrug-resistant PVL-positive
C-MRSA isolates usually emerge when they had become
responsible for hospital infections. Diep et al. [34] also
described a USA300 clone isolate that had accumulated
multiple resistance genes making it resistant to b-lactams,
ﬂuoroquinolones, tetracycline, macrolides, clindamycin and
mupirocin [34]. In San Francisco and Boston, multidrug-resis-
tant USA300 strains were found to spread rapidly among
men who have sex with men [34]. In the present study,
10
0
80 PFGE pattern Strains CA(1)/HA(2) FQ agr Toxin genes spa type
ST20070665 2 S 3 etd edin t044
ST20070729 1 S 3 etd edin t044
ST20070668 1 S 3 etd edin t044
ST20070727 2 S 3 etd edin t044
ST20070677 2 S 3 etd edin t044
ST20070693 2 S 3 etd edin t044
ST20080238 2 S 3 etd edin t044
ST20080327 2 S 3 etd edin t044
ST20070747 2 S 3 etd edin t044
ST20071030 2 S 3 etd edin t044
ST20080343 2 S 3 etd edin t044
ST20070691 2 S 3 etd edin t044
ST20070635 1 S 3 etd edin t044
ST20070680 1 S 3 etd edin t4143
ST20070699 1 S 3 etd edin t044
ST20070736 1 S 3 etd edin t044
ST20080206 1 S 3 etd edin t044
ST20080324 1 S 3 etd edin t044
ST20070749 2 S 3 etd edin t044
ST20070641 2 R 3 etd edin t044
ST20070681 2 R 3 etd edin t044
ST20070732 2 R 3 etd edin t044
etd edin t044ST20070738 2 R 3
ST20070751 2 R 3 etd edin t044
ST20070659 1 S 3 etd edin t044
ST20080210 2 R 3 etd edin t044
ST20080515 2 R 3 etd edin t044
ST20070753 2 R 3 etd edin t044
ST20070757 2 R 3 etd edin t044
ST20080193 2 R 3 etd edin t044
ST20080198 2 R 3 etd edin t044
ST20080199 2 R 3 etd edin t044
ST20080345 2 R 3 etd edin t044
ST20080200 2 S 3 etd edin t044
ST20080331 2 R 3 etd edin t044
ST20070717 2 S 3 etd edin t044
ST20080212 2 R 3 etd edin t044
ST20080340 2 R 3 etd edin t044
ST20070638 2 R 3 etd edin t044
ST20080239 2 R 3 etd edin t044
ST20070704 2 R 3 etd edin t044
etd edin t044ST20080192 1 S 3
ST20070703 2 R 3 etd edin t044
ST20080363 1 S 3 etd edin t044
ST20070711 2 R 3 etd edin t044
ST20070723 2 R 3 etd edin t044
FIG. 1. Dendrogram constructed from
the schematic representation of the
pulsed-ﬁeld gel electrophoresis types of
methicillin-resistant Staphylococcus aureus
isolates with their genetic characteris-
tics, such as agr allele group, toxin gene
content and spa type. Fluoroquinolone
(FQ) susceptibility is given: R, resistant;
S, susceptible. Strains were community-
acquired (CA = 1) or hospital-acquired
(HA = 2).
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ﬂuoroquinolone-resistant PVL-positive MRSA were solely
detected in the hospital setting (mainly in the dermatology
unit), suggesting that they were transmitted by healthcare
workers or by environmental contamination. We found a
very high rate of nasal carriage of PVL-positive MRSA in the
hospital setting, especially among patients and staff of the
dermatology unit. The risk that multidrug-resistant ST80-IV
strains will spread to the community in Algeria is a worrying
prospect.
Recent data suggest that nasal colonization may play a less
important role than skin–skin and skin–fomite contact in the
pathogenesis of C-MRSA infection. A common feature of
outbreak and endemic C-MRSA infections is the lack of an
identiﬁable endogenous source of MRSA, such as asymptom-
atic carriage in the anterior nares [35]. C-MRSA might thus
be acquired preferentially from other body sites or from
contaminated environments. The relatively low rate of nasal
carriage observed in the Algiers community is similar to that
reported elsewhere [35].
In conclusion, PVL-positive MRSA are endemic in both the
community and hospital settings in Algiers, the capital city of
Algeria. If the PVL-positive USA300 clone has spread all over
the USA, the ST80-IV is also a highly epidemic clone which
has already spread in Algeria.
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